Randomized Phase II/III Study Of Venetoclax (Abt 199) Plus Chemoimmunotherapy For Myc/Bcl2 Double-Hit And Double Expressing Lymphomas

Protocol No
ALLIANCE-A051701-DLBCL
Principal Investigator
Timothy Fenske
Phase
II/III
Summary
This study is being done to answer the following question: “Can we lower the chance of lymphoma returning or getting worse by adding a new drug to the usual combination of drugs?” We are doing this study because we want to find out if this approach is better or worse than the usual approach for lymphoma. The usual approach is defined as care most people get for double-hit or double expressing lymphoma.
Description
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: